Skip to main content

Table 5 Multivariate analysis

From: Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT

  Relapse NRM Acute GVHD Chronic GVHD LFS OS
  p value HR (95 % CI) p value HR (95 % CI) p value OR (95 % CI) p value HR (95 % CI) p value HR (95 % CI) p value HR (95 % CI)
RIC vs. MAC
 All 0.07 1.31 (0.98–1.75) 0.76 0.95 (0.69–1.31) 0.32 0.82 (0.55–1.21) 0.21 0.80 (0.56–1.14) 0.27 1.13 (0.91–1.40) 0.44 1.09 (0.87–1.36)
 AML 0.09 1.34 (0.95–1.87) 0.17 0.78 (0.54–1.12)      0.74 1.04 (0.81–1.34) 0.79 0.97 (0.75–1.25)
 ALL 0.5 1.23 (0.67–2.26) 0.18 1.5 (0.83–2.72)      0.17 1.34 (0.88–2.05) 0.10 1.44 (0.94–2.22)
Age at SCT
 1. <30 (ref)   1.00   1.00   1.00   1.00   1.00   1.00
 2. (30–40) vs. 1 0.91 1.02 (0.68–1.54) 0.27 0.79 (0.51–1.20) 0.98 1.01 (0.60–1.70) 0.25 0.75 (0.46–1.22) 0.47 0.90 (0.67–1.20) 0.52 0.91 (0.67–1.23)
 3. (40–50) vs. 2 0.43 0.84 (0.55–1.28) 0.74 1.08 (0.69–1.69) 0.98 1.01 (0.58–1.77) 0.70 0.91 (0.56–1.48) 0.74 0.95 (0.70–1.29) 0.79 0.96 (0.69–1.32)
 4. ≥ 50 vs. 3 0.11 1.33 (0.93–1.90) 0.48 0.87 (0.59–1.28) 0.06 1.62 (0.98–2.70) 0.44 1.18 (0.77–1.79) 0.52 1.09 (0.84–1.42) 0.79 1.04 (0.79–1.36)
ALL vs. AML 0.04 1.39 (1.021.91) 0.37 1.16 (0.84–1.61) 0.65 1.10 (0.73–1.66) 0.50 1.13 (0.79–1.63) 0.03 1.28 (1.021.61) 0.03 1.30 (1.031.64)
Status at SCT
 CR1 (ref)   1.00   1.00   1.00   1.00   1.00   1.00
  ≥ CR2 vs. CR1 0.05 1.46 (1.012.13) 0.45 1.15 (0.80–1.63) 0.35 1.24 (0.80–1.92) 0.23 1.25 (0.87–1.78) 0.05 1.30 (1.001.67) 0.01 1.40 (1.071.83)
 Active dis. vs. CR1 <104 4.43 (3.206.12) 0.0002 1.86 (1.342.59) 0.85 1.04 (0.68–1.60) 0.45 1.17 (0.78–1.75) <104 2.94 (2.343.70) <104 2.92 (2.303.72)
PB vs. BM 0.85 1.03 (0.77–1.37) 0.59 1.09 (0.80–1.48) 0.0008 1.96 (1.32–2.92) 0.005 1.64 (1.162.30) 0.63 1.05 (0.85–1.30) 0.58 1.06 (0.85–1.32)
PT-Cy-based vs. other 0.94 0.99 (0.72–1.36) 0.02 0.63 (0.440.92) 0.11 0.69 (0.44–1.09) 0.46 1.15 (0.79–1.69) 0.10 0.82 (0.64–1.04) 0.16 0.83 (0.65–1.07)
Year of SCT
 2001–2005 (ref)   1.00   1.00   1.00   1.00   1.00   1.00
 2005–2007 0.86 1.08 (0.48–2.43) 0.74 0.89 (0.45–1.77) 0.62 1.24 (0.44–3.51) 0.17 2.03 (0.74–5.56) 0.89 0.96 (0.57–1.63) 0.84 1.06 (0.61–1.83)
 2008–2012 0.98 0.99 (0.47–2.09) 0.22 0.68 (0.36–1.27) 0.27 1.68 (0.67–4.22) 0.14 2.04 (0.80–5.19) 0.40 0.81 (0.50–1.31) 0.60 0.87 (0.53–1.44)
  1. Active dis active disease, BM bone marrow, PT-Cy-based post-transplant cyclophosphamide associated to one calcineurin inhibitor and mycophenolate mofetyl, CR complete remission, GVHD graft-versus-host-disease, LFS leukemia-free survival, NRM non-relapse mortality, MAC myeloablative conditioning, OS overall survival, PB peripheral blood, Ref reference, RIC reduced intensity conditioning, SCT allogeneic stem cell transplantation